Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.

Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.

Cancer Immunol Res. 2018 Dec 4. doi: 10.1158/2326-6066.CIR-18-0085. [Epub ahead of print]

PMID:
30514793
2.

[In bacteria veritas: pronostic role of intestinal microbiote in cancer therapy].

Messaoudene M, Derosa L, Belkaid W, Routy B.

Med Sci (Paris). 2018 Aug-Sep;34(8-9):657-659. doi: 10.1051/medsci/20183408009. Epub 2018 Sep 19. French. No abstract available.

PMID:
30230457
3.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

PMID:
29229601
4.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
5.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

6.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

7.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
8.

Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.

Messaoudene M, Frazao A, Gavlovsky PJ, Toubert A, Dulphy N, Caignard A.

Front Immunol. 2017 Jun 12;8:683. doi: 10.3389/fimmu.2017.00683. eCollection 2017.

9.

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.

Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A.

Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2.

10.

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L.

Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.

11.

NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.

Messaoudene M, Fregni G, Enot D, Jacquelot N, Neves E, Germaud N, Garchon HJ, Boukouaci W, Tamouza R, Chanal J, Avril MF, Toubert A, Zitvogel L, Rusakiewicz S, Caignard A.

Oncoimmunology. 2016 Mar 10;5(12):e1154251. doi: 10.1080/2162402X.2016.1154251. eCollection 2016.

12.

Immune Modifications in Fetal Membranes Overlying the Cervix Precede Parturition in Humans.

Marcellin L, Schmitz T, Messaoudene M, Chader D, Parizot C, Jacques S, Delaire J, Gogusev J, Schmitt A, Lesaffre C, Breuiller-Fouché M, Caignard A, Vaiman D, Goffinet F, Cabrol D, Gorochov G, Méhats C.

J Immunol. 2017 Feb 1;198(3):1345-1356. doi: 10.4049/jimmunol.1601482. Epub 2016 Dec 28.

13.

Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.

Messaoudene M, Périer A, Fregni G, Neves E, Zitvogel L, Cremer I, Chanal J, Sastre-Garau X, Deschamps L, Marinho E, Larousserie F, Maubec E, Avril MF, Caignard A.

PLoS One. 2015 Jul 28;10(7):e0133363. doi: 10.1371/journal.pone.0133363. eCollection 2015.

14.

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma.

Messaoudene M, Avril MF, Caignard A.

Oncoimmunology. 2014 Feb 14;3:e28048. eCollection 2014.

15.

Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma.

Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, Couturaud B, Girod A, Sastre-Garau X, Albert S, Guédon C, Deschamps L, Mitilian D, Cremer I, Jacquelot N, Rusakiewicz S, Zitvogel L, Avril MF, Caignard A.

Cancer Res. 2014 Jan 1;74(1):81-92. doi: 10.1158/0008-5472.CAN-13-1303. Epub 2013 Nov 13.

16.

Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.

Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril MF, Caignard A.

PLoS One. 2013 Oct 18;8(10):e76928. doi: 10.1371/journal.pone.0076928. eCollection 2013.

17.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L.

Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6.

Supplemental Content

Loading ...
Support Center